<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="ACETYLCHOLINESTERASE INHIBITORS" code="NO6DA-001" /></DRUG2>
<DESCRIPTION>Risk of excessive bradycardia (addition of the bradycardia inducing effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring, especially at the beginning of the administration of the substances together </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG2>
<DESCRIPTION>Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG2>
<DESCRIPTION>Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="GLINIDES" code="A10BX-001" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN " rxcui="5856">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
<ATC code="N01BB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
